We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Lurbinectedin

News List

Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers americanpharmaceuticalreview
August 11, 2021
Stand Up To Cancer® and Jazz Pharmaceuticals plc announce a three-year, $4 million research collaboration to explore new opportunities, including lurbinectedin in pediatric solid tumors and pan-RAF molecules in RAF- and RAS-mutated solid cancers.
FDA Grants Accelerated Approval Metastatic Small Cell Lung Cancer Treatment americanpharmaceuticalreview
June 29, 2020
The Food and Drug Administration (FDA) has granted accelerated approval to lurbinectedin (ZEPZELCA, Pharma Mar S.A.) for adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
FDA Grants Orphan Drug Designation to Lurbinectedin americanpharmaceuticalreview
August 06, 2018
PharmaMar announces that lurbinectedin has been granted orphan drug status by the FDA for the treatment of small cell lung cancer。